Clostridioides difficile
Fidaxomicin vs. vancomycin (Louie), faecal microbiota transplantation (van Nood) and bezlotoxumab (MODIFY).
- Trials
- 3
- Years
- 2011–2017
Sort
- 2017MODIFY I/IIRecurrence preventionIn 2,655 patients receiving antibiotics for Clostridium difficile infection, a single dose of bezlotoxumab reduced recurrent CDI at 12 weeks compared with placebo.Read →
- 2013van Nood FMTRecurrent CDIIn 43 patients with recurrent Clostridium difficile infection, faecal microbiota transplantation achieved cure more often than oral vancomycin.94% vs 31%Read →
- 2011Louie FidaxomicinInitial therapyIn 629 patients with Clostridium difficile infection, fidaxomicin reduced recurrence at 4 weeks compared with oral vancomycin with similar clinical cure.15.4% vs 25.3%Read →